Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Role of radiation dose in the risk of secondary leukemia after a solid tumor in childhood treated between 1980 and 1999.

Allard A, Haddy N, Le Deley MC, Rubino C, Lassalle M, Samsaldin A, Quiniou E, Chompret A, Lefkopoulos D, Diallo I, de Vathaire F.

Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1474-82. doi: 10.1016/j.ijrobp.2009.09.032. Epub 2010 Mar 19.

PMID:
20303670
2.

Incomplete penetrance of the predisposition to medulloblastoma associated with germ-line SUFU mutations.

Brugières L, Pierron G, Chompret A, Paillerets BB, Di Rocco F, Varlet P, Pierre-Kahn A, Caron O, Grill J, Delattre O.

J Med Genet. 2010 Feb;47(2):142-4. doi: 10.1136/jmg.2009.067751. Epub 2009 Oct 14.

PMID:
19833601
3.

Protective effect of copy number polymorphism of glutathione S-transferase T1 gene on melanoma risk in presence of CDKN2A mutations, MC1R variants and host-related phenotypes.

Chaudru V, Lo MT, Lesueur F, Marian C, Mohamdi H, Laud K, Barrois M, Chompret A, Avril MF, Demenais F, Bressac-de Paillerets B.

Fam Cancer. 2009;8(4):371-7. doi: 10.1007/s10689-009-9249-5. Epub 2009 May 31.

PMID:
19484507
4.

Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.

Kannengiesser C, Brookes S, del Arroyo AG, Pham D, Bombled J, Barrois M, Mauffret O, Avril MF, Chompret A, Lenoir GM, Sarasin A; French Hereditary Melanoma Study Group, Peters G, Bressac-de Paillerets B.

Hum Mutat. 2009 Apr;30(4):564-74. doi: 10.1002/humu.20845.

PMID:
19260062
5.

The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma.

Lesueur F, de Lichy M, Barrois M, Durand G, Bombled J, Avril MF, Chompret A, Boitier F, Lenoir GM; French Familial Melanoma Study Group, Bressac-de Paillerets B, Baccard M, Bachollet B, Berthet P, Bonadona V, Bonnetblanc JM, Caron O, Chevrant-Breton J, Cuny JF, Dalle S, Delaunay M, Demange L, De Quatrebarbes J, Doré JF, Frénay M, Fricker JP, Gauthier-Villars M, Gesta P, Giraud S, Gorry P, Grange F, Green A, Huiart L, Janin N, Joly P, Kérob D, Lasset C, Leroux D, Limacher JM, Longy M, Mansard S, Marrou K, Martin-Denavit T, Mateus C, Maubec E, Olivier-Faivre L, Orlandini V, Pujol P, Sassolas B, Stoppa-Lyonnet D, Thomas L, Vabres P, Venat L, Wierzbicka E, Zattara H.

Br J Cancer. 2008 Jul 22;99(2):364-70. doi: 10.1038/sj.bjc.6604470. Epub 2008 Jul 8.

6.

Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families.

Bougeard G, Sesboüé R, Baert-Desurmont S, Vasseur S, Martin C, Tinat J, Brugières L, Chompret A, de Paillerets BB, Stoppa-Lyonnet D, Bonaïti-Pellié C, Frébourg T; French LFS working group.

J Med Genet. 2008 Aug;45(8):535-8. doi: 10.1136/jmg.2008.057570. Epub 2008 May 29.

PMID:
18511570
7.

Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Antoniou AC, Spurdle AB, Sinilnikova OM, Healey S, Pooley KA, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Hofmann W, Sutter C, Niederacher D, Deissler H, Caldes T, Kämpjärvi K, Nevanlinna H, Simard J, Beesley J, Chen X; Kathleen Cuningham Consortium for Research into Familial Breast Cancer, Neuhausen SL, Rebbeck TR, Wagner T, Lynch HT, Isaacs C, Weitzel J, Ganz PA, Daly MB, Tomlinson G, Olopade OI, Blum JL, Couch FJ, Peterlongo P, Manoukian S, Barile M, Radice P, Szabo CI, Pereira LH, Greene MH, Rennert G, Lejbkowicz F, Barnett-Griness O, Andrulis IL, Ozcelik H; OCGN, Gerdes AM, Caligo MA, Laitman Y, Kaufman B, Milgrom R, Friedman E; Swedish BRCA1 and BRCA2 study collaborators, Domchek SM, Nathanson KL, Osorio A, Llort G, Milne RL, Benítez J, Hamann U, Hogervorst FB, Manders P, Ligtenberg MJ, van den Ouweland AM; DNA-HEBON collaborators, Peock S, Cook M, Platte R, Evans DG, Eeles R, Pichert G, Chu C, Eccles D, Davidson R, Douglas F; EMBRACE, Godwin AK, Barjhoux L, Mazoyer S, Sobol H, Bourdon V, Eisinger F, Chompret A, Capoulade C, Bressac-de Paillerets B, Lenoir GM, Gauthier-Villars M, Houdayer C, Stoppa-Lyonnet D; GEMO, Chenevix-Trench G, Easton DF; CIMBA.

Am J Hum Genet. 2008 Apr;82(4):937-48. doi: 10.1016/j.ajhg.2008.02.008. Epub 2008 Mar 20.

8.

Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumors.

Linger R, Dudakia D, Huddart R, Tucker K, Friedlander M, Phillips KA, Hogg D, Jewett MA, Lohynska R, Daugaard G, Richard S, Chompret A, Stoppa-Lyonnet D, Bonaïti-Pellié C, Heidenreich A, Albers P, Olah E, Geczi L, Bodrogi I, Daly PA, Guilford P, Fosså SD, Heimdal K, Tjulandin SA, Liubchenko L, Stoll H, Weber W, Einhorn L, McMaster M, Korde L, Greene MH, Nathanson KL, Cortessis V, Easton DF, Bishop DT, Stratton MR, Rapley EA.

Genes Chromosomes Cancer. 2008 Mar;47(3):247-52.

9.

[Prophylactic mastectomies and immediate breast reconstruction in patients at very high genetic risk: our experience with 14 cases].

Missana MC, Chompret A.

Ann Chir Plast Esthet. 2008 Aug;53(4):325-33. Epub 2007 Dec 4. French.

PMID:
18055089
10.

An unusual variant of diffuse retinoblastoma in an adult.

Khanfir K, Chompret A, Frau E, Bloch-Michel E, Tursz T, Le Cesne A.

Acta Oncol. 2008;47(5):973-4. No abstract available.

PMID:
17943473
11.

Methylation-associated PHOX2B gene silencing is a rare event in human neuroblastoma.

de Pontual L, Trochet D, Bourdeaut F, Thomas S, Etchevers H, Chompret A, Minard V, Valteau D, Brugieres L, Munnich A, Delattre O, Lyonnet S, Janoueix-Lerosey I, Amiel J.

Eur J Cancer. 2007 Nov;43(16):2366-72. Epub 2007 Aug 31.

12.

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, André F, Delaloge S, Tursz T, Kroemer G, Zitvogel L.

Nat Med. 2007 Sep;13(9):1050-9. Epub 2007 Aug 19.

PMID:
17704786
13.

Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD.

Pasini B, McWhinney SR, Bei T, Matyakhina L, Stergiopoulos S, Muchow M, Boikos SA, Ferrando B, Pacak K, Assie G, Baudin E, Chompret A, Ellison JW, Briere JJ, Rustin P, Gimenez-Roqueplo AP, Eng C, Carney JA, Stratakis CA.

Eur J Hum Genet. 2008 Jan;16(1):79-88. Epub 2007 Aug 1.

14.

BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma.

Monnerat C, Chompret A, Kannengiesser C, Avril MF, Janin N, Spatz A, Guinebretière JM, Marian C, Barrois M, Boitier F, Lenoir GM, Bressac-de Paillerets B.

Fam Cancer. 2007;6(4):453-61. Epub 2007 Jul 12.

PMID:
17624602
15.

New founder germline mutations of CDKN2A in melanoma-prone families and multiple primary melanoma development in a patient receiving levodopa treatment.

Kannengiesser C, Dalle S, Leccia MT, Avril MF, Bonadona V, Chompret A, Lasset C, Leroux D, Thomas L, Lesueur F, Lenoir G, Sarasin A, Bressac-de Paillerets B.

Genes Chromosomes Cancer. 2007 Aug;46(8):751-60.

PMID:
17492760
16.

Cutaneous phenotype and MC1R variants as modifying factors for the development of melanoma in CDKN2A G101W mutation carriers from 4 countries.

Goldstein AM, Chaudru V, Ghiorzo P, Badenas C, Malvehy J, Pastorino L, Laud K, Hulley B, Avril MF, Puig-Butille JA, Miniere A, Marti R, Chompret A, Cuellar F, Kolm I, Mila M, Tucker MA, Demenais F, Bianchi-Scarra G, Puig S, de-Paillerets BB.

Int J Cancer. 2007 Aug 15;121(4):825-31.

17.

[Oncogenetic consultation for breast cancer].

Chompret A, Noguès C, Stoppa-Lyonnet D.

Presse Med. 2007 Feb;36(2 Pt 2):357-63. Epub 2007 Jan 9. Review. French.

PMID:
17258685
18.

The contribution of germline rearrangements to the spectrum of BRCA2 mutations.

Casilli F, Tournier I, Sinilnikova OM, Coulet F, Soubrier F, Houdayer C, Hardouin A, Berthet P, Sobol H, Bourdon V, Muller D, Fricker JP, Capoulade-Metay C, Chompret A, Nogues C, Mazoyer S, Chappuis P, Maillet P, Philippe C, Lortholary A, Gesta P, Bézieau S, Toulas C, Gladieff L, Maugard CM, Provencher DM, Dugast C, Delvincourt C, Nguyen TD, Faivre L, Bonadona V, Frébourg T, Lidereau R, Stoppa-Lyonnet D, Tosi M.

J Med Genet. 2006 Sep;43(9):e49.

19.

Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents.

Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Bishop DT, Azizi E, Bergman W, Bianchi-Scarra G, Bruno W, Calista D, Albright LA, Chaudru V, Chompret A, Cuellar F, Elder DE, Ghiorzo P, Gillanders EM, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, Leachman SA, MacKie RM, Magnusson V, Mann GJ, Bishop JN, Palmer JM, Puig S, Puig-Butille JA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E; Lund Melanoma Study Group; Melanoma Genetics Consortium (GenoMEL).

J Med Genet. 2007 Feb;44(2):99-106. Epub 2006 Aug 11.

20.

Patients' characteristics and rate of Internet use to obtain cancer information.

Mancini J, Noguès C, Adenis C, Berthet P, Bonadona V, Chompret A, Coupier I, Eisinger F, Fricker JP, Gauthier-Villars M, Lasset C, Lortholary A, N'Guyen TD, Vennin P, Sobol H, Stoppa-Lyonnet D, Julian-Reynier C.

J Public Health (Oxf). 2006 Sep;28(3):235-7. Epub 2006 Jun 29.

PMID:
16809788
21.

Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS).

Andrieu N, Goldgar DE, Easton DF, Rookus M, Brohet R, Antoniou AC, Peock S, Evans G, Eccles D, Douglas F, Noguès C, Gauthier-Villars M, Chompret A, Van Leeuwen FE, Kluijt I, Benitez J, Arver B, Olah E, Chang-Claude J; EMBRACE; GENEPSO; GEO-HEBON; IBCCS Collaborators Group.

J Natl Cancer Inst. 2006 Apr 19;98(8):535-44.

22.

Impact of an information booklet on satisfaction and decision-making about BRCA genetic testing.

Mancini J, Noguès C, Adenis C, Berthet P, Bonadona V, Chompret A, Coupier I, Eisinger F, Fricker JP, Gauthier-Villars M, Lasset C, Lortholary A, N'Guyen TD, Vennin P, Sobol H, Stoppa-Lyonnet D, Julian-Reynier C.

Eur J Cancer. 2006 May;42(7):871-81. Epub 2006 Mar 23.

PMID:
16563745
23.

An ovarian dysgerminoma in Down syndrome. Hypothesis about the association.

Satgé D, Honoré L, Sasco AJ, Vekemans M, Chompret A, Réthoré MO.

Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:375-9.

PMID:
16515627
24.

[Clinical and genetic study in 22 patients with basal cell nevus syndrome].

Pruvost-Balland C, Gorry P, Boutet N, Magnaldo T, Mamelle G, Margulis A, Kolb F, Duvillard P, Spatz A, Brugières L, Chompret A, Avril MF.

Ann Dermatol Venereol. 2006 Feb;133(2):117-23. Review. French.

PMID:
16508594
25.

Genome-wide linkage screen for testicular germ cell tumour susceptibility loci.

Crockford GP, Linger R, Hockley S, Dudakia D, Johnson L, Huddart R, Tucker K, Friedlander M, Phillips KA, Hogg D, Jewett MA, Lohynska R, Daugaard G, Richard S, Chompret A, Bonaïti-Pellié C, Heidenreich A, Albers P, Olah E, Geczi L, Bodrogi I, Ormiston WJ, Daly PA, Guilford P, Fosså SD, Heimdal K, Tjulandin SA, Liubchenko L, Stoll H, Weber W, Forman D, Oliver T, Einhorn L, McMaster M, Kramer J, Greene MH, Weber BL, Nathanson KL, Cortessis V, Easton DF, Bishop DT, Stratton MR, Rapley EA.

Hum Mol Genet. 2006 Feb 1;15(3):443-51. Epub 2006 Jan 11.

PMID:
16407372
26.

The Y deletion gr/gr and susceptibility to testicular germ cell tumor.

Nathanson KL, Kanetsky PA, Hawes R, Vaughn DJ, Letrero R, Tucker K, Friedlander M, Phillips KA, Hogg D, Jewett MA, Lohynska R, Daugaard G, Richard S, Chompret A, Bonaïti-Pellié C, Heidenreich A, Olah E, Geczi L, Bodrogi I, Ormiston WJ, Daly PA, Oosterhuis JW, Gillis AJ, Looijenga LH, Guilford P, Fosså SD, Heimdal K, Tjulandin SA, Liubchenko L, Stoll H, Weber W, Rudd M, Huddart R, Crockford GP, Forman D, Oliver DT, Einhorn L, Weber BL, Kramer J, McMaster M, Greene MH, Pike M, Cortessis V, Chen C, Schwartz SM, Bishop DT, Easton DF, Stratton MR, Rapley EA.

Am J Hum Genet. 2005 Dec;77(6):1034-43. Epub 2005 Oct 24.

27.

[Malignant mesothelioma of the pleura revealed by bilateral spontaneous pneumothorax].

Margery J, Regnard JF, Chompret A, Le Tinier JY, Ruffie P.

Rev Pneumol Clin. 2005 Oct;61(5 Pt 1):332-3. French. No abstract available.

PMID:
16292162
28.

Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome.

Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugieres L, Chompret A, Bressac-de Paillerets B, Stoppa-Lyonnet D, Bonaiti-Pellie C, Frebourg T.

J Med Genet. 2006 Jun;43(6):531-3. Epub 2005 Oct 28.

29.

Melanocortin-1 receptor (MC1R) gene variants and dysplastic nevi modify penetrance of CDKN2A mutations in French melanoma-prone pedigrees.

Chaudru V, Laud K, Avril MF, Minière A, Chompret A, Bressac-de Paillerets B, Demenais F.

Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2384-90.

30.

Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases.

Albiges L, André F, Balleyguier C, Gomez-Abuin G, Chompret A, Delaloge S.

Ann Oncol. 2005 Nov;16(11):1846-7. Epub 2005 Jun 21. No abstract available.

PMID:
15972278
31.

Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma.

Laud K, Marian C, Avril MF, Barrois M, Chompret A, Goldstein AM, Tucker MA, Clark PA, Peters G, Chaudru V, Demenais F, Spatz A, Smith MW, Lenoir GM, Bressac-de Paillerets B; French Hereditary Melanoma Study Group.

J Med Genet. 2006 Jan;43(1):39-47. Epub 2005 Jun 3.

32.

Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene.

Hughes DJ, Ginolhac SM, Coupier I, Barjhoux L, Gaborieau V, Bressac-de-Paillerets B, Chompret A, Bignon YJ, Uhrhammer N, Lasset C, Giraud S, Sobol H, Hardouin A, Berthet P, Peyrat JP, Fournier J, Nogues C, Lidereau R, Muller D, Fricker JP, Longy M, Toulas C, Guimbaud R, Yannoukakos D, Mazoyer S, Lynch HT, Lenoir GM, Goldgar DE, Stoppa-Lyonnet D, Sinilnikova OM.

Int J Cancer. 2005 Nov 1;117(2):230-3.

33.

Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers.

Hughes DJ, Ginolhac SM, Coupier I, Corbex M, Bressac-de-Paillerets B, Chompret A, Bignon YJ, Uhrhammer N, Lasset C, Giraud S, Hardouin A, Berthet P, Peyrat JP, Fournier J, Nogues C, Lidereau R, Muller D, Fricker JP, Longy M, Toulas C, Guimbaud R, Maugard C, Olschwang S, Yannoukakos D, Durocher F, Moisan AM, Simard J, Mazoyer S, Lynch HT, Szabo C, Lenoir GM, Goldgar DE, Stoppa-Lyonnet D, Sinilnikova OM.

Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):265-7.

34.

Significant contribution of germline BRCA2 rearrangements in male breast cancer families.

Tournier I, Paillerets BB, Sobol H, Stoppa-Lyonnet D, Lidereau R, Barrois M, Mazoyer S, Coulet F, Hardouin A, Chompret A, Lortholary A, Chappuis P, Bourdon V, Bonadona V, Maugard C, Gilbert B, Nogues C, Frébourg T, Tosi M.

Cancer Res. 2004 Nov 15;64(22):8143-7.

35.

Sex ratio among the offspring of BRCA mutation carriers.

Feunteun J, Chompret A, Helbling-Leclerc A, Stoppa-Lyonnet D, Belotti M, Noguès C, Bonaïti-Pellié C.

JAMA. 2004 Aug 11;292(6):687-8. No abstract available.

PMID:
15304464
36.

Sex differences in cancer risk among germline p53 mutation carriers.

Chompret A, Brugières L, Bonaïti-Pellié C, Feunteun J.

Br J Cancer. 2004 Aug 2;91(3):603-4. No abstract available.

37.

Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families.

Chaudru V, Chompret A, Bressac-de Paillerets B, Spatz A, Avril MF, Demenais F.

J Natl Cancer Inst. 2004 May 19;96(10):785-95.

PMID:
15150307
38.

Surgical procedure in patients with ovarian cancer diagnosed at the time of prophylactic oophorectomy. Analysis of two cases, literature review and surgical implications.

Morice P, Pautier P, Delaloge S, Spatz A, Chompret A.

Eur J Obstet Gynecol Reprod Biol. 2004 Apr 15;113(2):251-4. Review.

PMID:
15063971
39.

Genetic epidemiology of neuroblastoma: a study of 426 cases at the Institut Gustave-Roussy in France.

Shojaei-Brosseau T, Chompret A, Abel A, de Vathaire F, Raquin MA, Brugières L, Feunteun J, Hartmann O, Bonaïti-Pellié C.

Pediatr Blood Cancer. 2004 Jan;42(1):99-105.

PMID:
14752801
40.

PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor.

Chompret A, Kannengiesser C, Barrois M, Terrier P, Dahan P, Tursz T, Lenoir GM, Bressac-De Paillerets B.

Gastroenterology. 2004 Jan;126(1):318-21.

PMID:
14699510
41.

A 22-year French experience with solid tumors in children with Down syndrome.

Satgé D, Sasco AJ, Chompret A, Orbach D, Méchinaud F, Lacour B, Roullet B, Martelli H, Bergeron C, Bertrand Y, Lacombe D, Perel Y, Monteil P, Nelken B, Bertozzi AI, Munzer M, Kanold J, Bernard F, Vekemans MJ, Sommelet D.

Pediatr Hematol Oncol. 2003 Oct-Nov;20(7):517-29.

PMID:
12959856
42.

BRAF as a melanoma susceptibility candidate gene?

Laud K, Kannengiesser C, Avril MF, Chompret A, Stoppa-Lyonnet D, Desjardins L, Eychene A, Demenais F, Lenoir GM, Bressac-de Paillerets B; French Herediatary Melanoma Study Group.

Cancer Res. 2003 Jun 15;63(12):3061-5.

43.

[Clinical and molecular diagnosis of inherited breast-ovarian cancer].

Chompret A.

J Gynecol Obstet Biol Reprod (Paris). 2003 Apr;32(2):101-19. Review. French.

44.

A single Mediterranean, possibly Jewish, origin for the Val59Gly CDKN2A mutation in four melanoma-prone families.

Yakobson E, Eisenberg S, Isacson R, Halle D, Levy-Lahad E, Catane R, Safro M, Sobolev V, Huot T, Peters G, Ruiz A, Malvehy J, Puig S, Chompret A, Avril MF, Shafir R, Peretz H, Bressac-de Paillerets B.

Eur J Hum Genet. 2003 Apr;11(4):288-96.

45.

Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d'Oncologie Pédiatrique.

Le Deley MC, Leblanc T, Shamsaldin A, Raquin MA, Lacour B, Sommelet D, Chompret A, Cayuela JM, Bayle C, Bernheim A, de Vathaire F, Vassal G, Hill C; Société Française d'Oncologie Pédiatrique.

J Clin Oncol. 2003 Mar 15;21(6):1074-81.

PMID:
12637473
46.

Screening for TP53 rearrangements in families with the Li-Fraumeni syndrome reveals a complete deletion of the TP53 gene.

Bougeard G, Brugières L, Chompret A, Gesta P, Charbonnier F, Valent A, Martin C, Raux G, Feunteun J, Bressac-de Paillerets B, Frébourg T.

Oncogene. 2003 Feb 13;22(6):840-6.

PMID:
12584563
47.

BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutations.

Ginolhac SM, Gad S, Corbex M, Bressac-De-Paillerets B, Chompret A, Bignon YJ, Peyrat JP, Fournier J, Lasset C, Giraud S, Muller D, Fricker JP, Hardouin A, Berthet P, Maugard C, Nogues C, Lidereau R, Longy M, Olschwang S, Toulas C, Guimbaud R, Yannoukakos D, Szabo C, Durocher F, Moisan AM, Simard J, Mazoyer S, Lynch HT, Goldgar D, Stoppa-Lyonnet D, Lenoir GM, Sinilnikova OM.

Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):90-5.

48.

Geographical variation in the penetrance of CDKN2A mutations for melanoma.

Bishop DT, Demenais F, Goldstein AM, Bergman W, Bishop JN, Bressac-de Paillerets B, Chompret A, Ghiorzo P, Gruis N, Hansson J, Harland M, Hayward N, Holland EA, Mann GJ, Mantelli M, Nancarrow D, Platz A, Tucker MA; Melanoma Genetics Consortium.

J Natl Cancer Inst. 2002 Jun 19;94(12):894-903.

PMID:
12072543
49.

The Li-Fraumeni syndrome.

Chompret A.

Biochimie. 2002 Jan;84(1):75-82.

PMID:
11900879
50.

Genetic and environmental factors in cutaneous malignant melanoma.

Bressac-de-Paillerets B, Avril MF, Chompret A, Demenais F.

Biochimie. 2002 Jan;84(1):67-74. Review.

PMID:
11900878

Supplemental Content

Loading ...
Support Center